Head & Neck Surgery2022-03-09T17:24:37-06:00


A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician’s Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed on or After Two Lines of Therapy, Wenig.B

Background: Photoimmunotherapy (PIT) is a new cancer-targeted therapy. PIT is a combination drug and device anti-cancer treatment that utilizes monoclonal antibodies conjugated to a dye, that can be activated upon nonthermal 690 nm red light illumination to induce rapid cell death only at cells expressing the antigen and only after antibody binding to the cellular antigen. The requirement of light-induced activation and antigen-antibody binding to induce cell death enables the selective and specific destruction of tumor cells with minimum [...]

Incidence of Venous Thromboembolism in Head and neck Cancer Patients After Resection and Microvascular Free Flap Reconstruction, Wenig.B

Background: Venous thromboembolism (VTE) is a disease process characterized by blood clot formation in the deep veins of the lower extremities, known as deep vein thrombosis. In some, a blood clot may dislodge and travel into the vessels of the lungs causing a pulmonary embolism (PE). The incidence of this disease is increased by factors that 1) cause damage to blood vessels, 2) decrease blood circulation, and 3) increase thickness of the blood. Head and neck cancer patients who [...]

Go to Top